[
  {
    "ts": null,
    "headline": "Basal Cell Nevus Syndrome Market Growth Accelerates with Novel Therapies and Clinical Developments | DelveInsight",
    "summary": "DelveInsight's Basal Cell Nevus Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, basal cell nevus syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).",
    "url": "https://finnhub.io/api/news?id=941d6819fe93b44788ceda5aaa0193539c57a630dd517df21041e1628f483780",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761600660,
      "headline": "Basal Cell Nevus Syndrome Market Growth Accelerates with Novel Therapies and Clinical Developments | DelveInsight",
      "id": 137235650,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "DelveInsight's Basal Cell Nevus Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, basal cell nevus syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).",
      "url": "https://finnhub.io/api/news?id=941d6819fe93b44788ceda5aaa0193539c57a630dd517df21041e1628f483780"
    }
  },
  {
    "ts": null,
    "headline": "3 Dividend-Paying Drug Stocks to Buy at a Discount",
    "summary": "Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying?",
    "url": "https://finnhub.io/api/news?id=8279545e1f4f5bdecd28252969f8e5e1a2b2d7c97b2bd40da73ad2885e5d5e61",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761588000,
      "headline": "3 Dividend-Paying Drug Stocks to Buy at a Discount",
      "id": 137231008,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying?",
      "url": "https://finnhub.io/api/news?id=8279545e1f4f5bdecd28252969f8e5e1a2b2d7c97b2bd40da73ad2885e5d5e61"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors",
    "summary": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=35acfcac1993f7903874372cdfbab0bfe3c55159ada17e4d5067ca65ed072c80",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761583260,
      "headline": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors",
      "id": 137253842,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=35acfcac1993f7903874372cdfbab0bfe3c55159ada17e4d5067ca65ed072c80"
    }
  },
  {
    "ts": null,
    "headline": "What's in Store for These 5 Pharma Bigwigs This Earnings Season?",
    "summary": "As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.",
    "url": "https://finnhub.io/api/news?id=057f3ad06e55bc44adb41ef797b5ff64f324132986bd4b6e788158e89c3b0d3c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761577500,
      "headline": "What's in Store for These 5 Pharma Bigwigs This Earnings Season?",
      "id": 137230292,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.",
      "url": "https://finnhub.io/api/news?id=057f3ad06e55bc44adb41ef797b5ff64f324132986bd4b6e788158e89c3b0d3c"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Says New Data Show Efficacy of Sotyktu in Psoriatic Arthritis, Lupus",
    "summary": "Bristol-Myers Squibb (BMY) said Monday that new data from a pivotal phase 3 trial showed that its ps",
    "url": "https://finnhub.io/api/news?id=33d8f4116bd932b46d567e3a7677f38f61b3712be4301a46b0e8570aa7a5a8c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761577466,
      "headline": "Bristol-Myers Squibb Says New Data Show Efficacy of Sotyktu in Psoriatic Arthritis, Lupus",
      "id": 137228877,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb (BMY) said Monday that new data from a pivotal phase 3 trial showed that its ps",
      "url": "https://finnhub.io/api/news?id=33d8f4116bd932b46d567e3a7677f38f61b3712be4301a46b0e8570aa7a5a8c0"
    }
  },
  {
    "ts": null,
    "headline": "Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
    "summary": "Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=847df37059b3730bd7573f23206a09ebe502e2248fabe73acf62b29da4d1dae3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761573615,
      "headline": "Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
      "id": 137228878,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=847df37059b3730bd7573f23206a09ebe502e2248fabe73acf62b29da4d1dae3"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?",
    "summary": "Bristol-Myers Squibb's Q3 results hinge on rising demand for new therapies like Opdivo and Camzyos amid legacy-drug declines.",
    "url": "https://finnhub.io/api/news?id=ea1afeadec764e7dde5d7f19d3e2a2189016a9e6a88b3e31507606530dc6ae61",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761571020,
      "headline": "Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?",
      "id": 137228785,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb's Q3 results hinge on rising demand for new therapies like Opdivo and Camzyos amid legacy-drug declines.",
      "url": "https://finnhub.io/api/news?id=ea1afeadec764e7dde5d7f19d3e2a2189016a9e6a88b3e31507606530dc6ae61"
    }
  },
  {
    "ts": null,
    "headline": "Ahead of Bristol Myers (BMY) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics",
    "summary": "Besides Wall Street's top-and-bottom-line estimates for Bristol Myers (BMY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.",
    "url": "https://finnhub.io/api/news?id=0f71656ed4e57c9e6fcaab1feba0542d2e6051d621600df726866d4fe90332b9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761570903,
      "headline": "Ahead of Bristol Myers (BMY) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics",
      "id": 137228880,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Besides Wall Street's top-and-bottom-line estimates for Bristol Myers (BMY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.",
      "url": "https://finnhub.io/api/news?id=0f71656ed4e57c9e6fcaab1feba0542d2e6051d621600df726866d4fe90332b9"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus",
    "summary": "PRINCETON, N.J., October 27, 2025--BMS Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus",
    "url": "https://finnhub.io/api/news?id=f630e7877e691c2c55d3aa3f98fd586dd8fbe7a87d36135eb7ffdbea9b35dc6d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761562740,
      "headline": "Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus",
      "id": 137228881,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., October 27, 2025--BMS Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus",
      "url": "https://finnhub.io/api/news?id=f630e7877e691c2c55d3aa3f98fd586dd8fbe7a87d36135eb7ffdbea9b35dc6d"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: Earnings Champion Valued Like A Loser",
    "summary": "Bristol-Myers Squibb Company may be undervalued despite strong earnings, M&A, and growth prospects. Click for my BMY earnings preview update.",
    "url": "https://finnhub.io/api/news?id=57a72a36dc8c86c2af415ab0caa3236e486fd55bb7f2093156d335de86e1a019",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761556397,
      "headline": "Bristol-Myers Squibb: Earnings Champion Valued Like A Loser",
      "id": 137227841,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160008492/image_2160008492.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb Company may be undervalued despite strong earnings, M&A, and growth prospects. Click for my BMY earnings preview update.",
      "url": "https://finnhub.io/api/news?id=57a72a36dc8c86c2af415ab0caa3236e486fd55bb7f2093156d335de86e1a019"
    }
  },
  {
    "ts": null,
    "headline": "Novartis to Acquire Avidity Biosciences for $72 per Share",
    "summary": "Avidity Biosciences (RNA) has agreed to be acquired by Novartis (NVS) for $72 per share in a deal th",
    "url": "https://finnhub.io/api/news?id=dbc8c277643503cee94d9cd338441320278f35097cc41fc1e9cb35738f7f2635",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761553908,
      "headline": "Novartis to Acquire Avidity Biosciences for $72 per Share",
      "id": 137228524,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Avidity Biosciences (RNA) has agreed to be acquired by Novartis (NVS) for $72 per share in a deal th",
      "url": "https://finnhub.io/api/news?id=dbc8c277643503cee94d9cd338441320278f35097cc41fc1e9cb35738f7f2635"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers achieves positive results for Sotyktu in psoriatic arthritis and lupus",
    "summary": "Bristol Myers Squibb announces 52-week data from a Phase 3 study confirming the efficacy and safety of Sotyktu in patients with active psoriatic arthritis who have not received biologic therapy.The...",
    "url": "https://finnhub.io/api/news?id=b6faa05606a6b3d1ea5aa43ca49d1e9577818f81503bfa61d7cc09e4e991cae6",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761553233,
      "headline": "Bristol Myers achieves positive results for Sotyktu in psoriatic arthritis and lupus",
      "id": 137227592,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol Myers Squibb announces 52-week data from a Phase 3 study confirming the efficacy and safety of Sotyktu in patients with active psoriatic arthritis who have not received biologic therapy.The...",
      "url": "https://finnhub.io/api/news?id=b6faa05606a6b3d1ea5aa43ca49d1e9577818f81503bfa61d7cc09e4e991cae6"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers presents positive results in autoimmune diseases",
    "summary": "Bristol Myers Squibb announces Phase 1 results of its experimental cell therapy NEX-T in 71 patients with scleroderma, lupus, and inflammatory myopathies.The data, presented at the ACR 2025...",
    "url": "https://finnhub.io/api/news?id=43d84f2a9355be27d1d21083d76a79535b08d918968a4ffd9da63f3c5fa415fb",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761552727,
      "headline": "Bristol Myers presents positive results in autoimmune diseases",
      "id": 137227588,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol Myers Squibb announces Phase 1 results of its experimental cell therapy NEX-T in 71 patients with scleroderma, lupus, and inflammatory myopathies.The data, presented at the ACR 2025...",
      "url": "https://finnhub.io/api/news?id=43d84f2a9355be27d1d21083d76a79535b08d918968a4ffd9da63f3c5fa415fb"
    }
  },
  {
    "ts": null,
    "headline": "Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb",
    "summary": "Advances made in preclinical pipeline addressing neurodegenerative diseases Evotec receives US$ 25 m payment to support continued progression of joint programs HAMBURG, DE / ACCESS Newswire / October 27, 2025 / Evotec SE (Frankfurt Stock Exchange: ...",
    "url": "https://finnhub.io/api/news?id=5802f04169f46929fa87c12895ca828bd6d4093771ae31a263cdde5d2e1d60df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761547800,
      "headline": "Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb",
      "id": 137228883,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Advances made in preclinical pipeline addressing neurodegenerative diseases Evotec receives US$ 25 m payment to support continued progression of joint programs HAMBURG, DE / ACCESS Newswire / October 27, 2025 / Evotec SE (Frankfurt Stock Exchange: ...",
      "url": "https://finnhub.io/api/news?id=5802f04169f46929fa87c12895ca828bd6d4093771ae31a263cdde5d2e1d60df"
    }
  }
]